• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences

Opinion
Video

Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) while also considering how these factors align or differ from patient preferences regarding treatment duration, adverse effect profiles, and lifestyle impact.

Related Videos
1 expert in this video
1 expert in this video
4 experts are featured in this series.
1 expert in this video
5 experts in this video
1 expert in this video
5 experts in this video
4 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.